Sanofi Consumer Healthcare India growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Dec 2025
+21.2%
+14.2%
+11.7%
+32.7%
+32.7%
+26.8%
+40.7%
−36.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SANOFICONR₹3,322.80

Sanofi Consumer Healthcare India Limited

· Pharma & Health
₹ CrorePeersPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹7,642 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/12/2024
FY26
31/12/2025
Last 12M
30/09/2026
Revenue Growth—+21.2—
EBITDA Growth—+14.2—
EBIT Growth—+11.7—
Net Income Growth—+32.7—
EPS Growth—+32.7—
Total Assets Growth—+26.8—
Total Equity Growth—+40.7—
Cash from Operations Growth—-36.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.